Reduced ferroxidase activity in the cerebrospinal fluid from patients with Parkinson's disease
Abstract
Recent evidence suggest the implication of transition metals leading to overproduction of free radicals as a possible causal factor in the death of nigral cells associated to Parkinson's disease (PD). Iron depots in the basal ganglia of PD patients have been described; in addition, contents of nigral copper have been found decreased, while its concentration in cerebrospinal fluid (CSF) is raised, particularly the free form of the metal. To search for a possible link between altered copper concentrations and PD, we advanced the hypothesis that ferroxidase activity of ceruloplasmin is decreased in the CSF of PD patients. We studied 35 untreated PD patients, 14 L-3,4-dihydroxyphenylalanine (L-DOPA)-treated PD patients and 26 controls. Both CSF ferroxidase activity and CSF copper content were measured and correlated with the clinical stage of the disease. We found that untreated PD patients had a significant reduction of 40% in CSF ferroxidase while CSF copper was slightly increased as compared with both the values in L-DOPA-treated PD patients and controls. We also found that the fraction of copper linked to ferroxidase in untreated PD is inversely related to the clinical stage of the disease.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
A contributing factor to the increased iron accumulation in Parkinson's disease might be increased DMT1 activity or decreased ferroxidase activity of ceruloplasmin, both of which would increase total intracellular iron.
“A contributing factor to the increased iron accumulation in Parkinson’s disease might be increased DMT1 activity or decreased ferroxidase activity of ceruloplasmin, both of which would increase total intracellular iron, as reported in an animal model of Parkinson’s disease109 and in patients.131–134”
From The role of iron in brain ageing and neurodegenerative disorders (2014) · cites this paper as [131]
Reduced ferroxidase activity of ceruloplasmin was noted in the CSF of patients with Parkinson's disease together with increased CSF copper concentrations by comparison with controls, a condition which could contribute to increased mobilisation of reactive iron and oxidative stress.
“Reduced ferroxidase activity of ceruloplasmin was noted in the CSF of patients with Parkinson’s disease together with increased CSF copper concentrations by comparison with controls,131 a condition which could contribute to the increased mobilisation of reactive iron and oxidative stress reported in Parkinson’s disease.”
From The role of iron in brain ageing and neurodegenerative disorders (2014) · cites this paper as [131]
The citation lists haven’t been fetched yet
References 21 · Cited by 92
- Authors
- Boll, M.-C., Sotelo, J., Otero, E., Alcaraz-Zubeldia, M., & Rios, C.
- Affiliations
- Instituto Nacional de Neurología y Neurocirugía (MX)
- Venue
- Neuroscience Letters
- Publisher
- Elsevier BV
- Published
- 1999-04
- Volume
- 265
- Issue
- 3
- Pages
- 155-158
- ISSN
- 0304-3940 (ISSN-L)
- OpenAlex
- W2070758185
- Cited by
- 92
- References
- 21
- Citations by year
- 2026: 1 · 2025: 1 · 2023: 3 · 2022: 3 · 2021: 5 · 2020: 3 · 2019: 5 · 2018: 3 · 2017: 7 · 2016: 4 · 2015: 6 · 2014: 8 · 2013: 5 · 2012: 1
- FWCI
- 2.24
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Neuroscience Letters (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Neuroscience › Neurology › Neurological diseases and metabolism
- Health Sciences › Nursing › Nutrition and Dietetics › Trace Elements in Health
- Keywords
- Parkinson's disease, ferroxidase activity, ceruloplasmin, cerebrospinal fluid, copper, iron, free radicals, L-dopa treatment, clinical stage, basal ganglia iron deposition, neurodegeneration
- MeSH terms
- Aged, Antiparkinson Agents, Ceruloplasmin, Copper, Enzyme Activation, Female, Humans, Iron, Levodopa, Male, Middle Aged, Parkinson Disease, Oxidative Stress
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
